Gain Therapeutics (GANX) Accounts Payables (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Accounts Payables of $1.5 million for Q1 2026, down 31.82% year-over-year from $2.2 million in Q1 2025, and up 81.81% quarter-over-quarter from $825027.0 in Q4 2025.
Gain Therapeutics (GANX) Accounts Payables (2020 - 2026) Analysis & Trends
Gain Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Accounts Payables fell 31.82% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 31.82% YoY), while the FY2025 annual figure was $825027.0, down 12.81% from the prior year.
- Accounts Payables for Q1 2026 stood at $1.5 million, up from $825027.0 in the prior quarter.
- The five-year high for Accounts Payables was $2.7 million in Q2 2025, with the low at $825027.0 in Q4 2025.
- The 5-year median for Accounts Payables is $1.4 million (2024), against an average of $1.5 million.
- The sharpest annual moves came in 2022 and 2024: Accounts Payables jumped 190.13% in 2022, then slumped 36.52% in 2024.
- Gain Therapeutics' Accounts Payables stood at $1.6 million in 2022, then retreated by 20.05% to $1.3 million in 2023, then dropped by 27.21% to $946259.0 in 2024, then declined by 12.81% to $825027.0 in 2025, then surged by 81.81% to $1.5 million in 2026.
- Business Quant data shows GANX's Accounts Payables at $1.5 million in Q1 2026, $825027.0 in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | 1.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.22 Mn |
| Mar 31, 2026 | 1.50 Mn |
| Dec 31, 2025 | 825,027.00 |
| Sep 30, 2025 | 1.58 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Mar 31, 2025 | 2.20 Mn |
| Dec 31, 2024 | 946,259.00 |
| Sep 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 2.05 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Dec 31, 2023 | 1.30 Mn |
| Sep 30, 2023 | 1.38 Mn |
| Jun 30, 2023 | 900,000.00 |
| Mar 31, 2023 | 2.21 Mn |
| Dec 31, 2022 | 1.63 Mn |
| Sep 30, 2022 | 1.02 Mn |
| Jun 30, 2022 | 948,902.00 |
| Mar 31, 2022 | 2.12 Mn |
| Dec 31, 2021 | 560,479.00 |
| Sep 30, 2021 | 789,387.00 |